Research Articles | Page 8 | Aplastic Anemia & MDS International Foundation

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Research Articles

Article Title Original Publication Date Journal Bone Marrow Disease
Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT Sep 2016 Ann Hematol myelodysplastic syndromes (MDS)
Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function Apr 2014 Ann Hematol myelodysplastic syndromes (MDS)
Prognostic impact of the number of methylated genes in myelodysplastic syndromes and acute myeloid leukemias treated with azacytidine. Jun 2013 Ann Hematol myelodysplastic syndromes (MDS)
Predictors of early mortality after rabbit antithymocyte globulin as first-line treatment in severe aplastic anemia Aug 2017 Ann Hematol aplastic anemia
Efficacy and safety of deferasirox in myelodysplastic syndromes Feb 2013 Ann Hematol myelodysplastic syndromes (MDS)
Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes. Sep 2013 Ann Hematol myelodysplastic syndromes (MDS)
Asymptomatic cerebral bleeds in patients with aplastic anemia. Mar 2012 Ann Hematol aplastic anemia
Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide May 2014 Ann Hematol myelodysplastic syndromes (MDS)
Development of a disease-specific quality of life questionnaire for patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria (QLQ-AA/PNH)-report on phases I and II Nov 2016 Ann Hematol paroxysmal nocturnal hemoglobinuria (PNH)
Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol Aug 2016 Ann Hematol myelodysplastic syndromes (MDS)